MedTrace Logo

A Trial of SHR-1139 in Healthy Volunteers

NCT07078695 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-03-19

No results posted yet for this study

Summary

The purpose of this study is to assess safety, PK and immunogenicity profile of a single dose of SHR-1139 in healthy volunteers

Conditions

Interventions

DRUG

SHR-1139 Injection

Single dose of SHR-1139 given subcutaneously (dose level 1 )

DRUG

SHR-1139 Injection

Single dose of SHR-1139 given subcutaneously (dose level 2 )

DRUG

SHR-1139 Injection

Single dose of SHR-1139 given intravenously (dose level 3)

Sponsors & Collaborators

  • Atridia Pty Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-08-19
Primary Completion
2026-09-30
Completion
2026-09-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07078695 on ClinicalTrials.gov